None

None

None

None

None

None

Pharmacokinetics and Safety of SHR0302 in Patients With Hepatic Impairment

Study to Evaluate Pharmacokinetics and Safety of SHR0302 in Patients With Mild, Moderate Hepatic Impairment and Normal Liver Function in Phase I Clinical Study

Study of Pexidartinib in Participants With Moderate Hepatic Impairment Compared With Healthy Participants

The pharmacokinetics of a single dose of pexidartinib will be investigated in participants with impaired hepatic function and compared with healthy control participants with normal hepatic function.

To Evaluate the Safety and Pharmacokinetics of Parscaclisib in Participants With Normal Hepatic Function and Hepatic Impairment.  

The purpose of the study is to evaluate the pharmacokinetics and safety of parsaclisib in participants With normal hepatic function and participants with hepatic impairment.

Study to Evaluate the Pharmacokinetics (PK) of E7090 and Its Metabolite in Participants With Mild and Moderate Hepatic Impairment Compared to Healthy Participants

The primary purpose of the study is to evaluate the effects of mild and moderate hepatic impairment on PK of E7090 after a single dose administration.